181 related articles for article (PubMed ID: 32253426)
1. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
[TBL] [Abstract][Full Text] [Related]
2. Bronchoalveolar Lavage Fluid Reflects a T
Friedmann D; Unger S; Keller B; Rakhmanov M; Goldacker S; Zissel G; Frye BC; Schupp JC; Prasse A; Warnatz K
Front Immunol; 2020; 11():616832. PubMed ID: 33613543
[TBL] [Abstract][Full Text] [Related]
3. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
5. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
[TBL] [Abstract][Full Text] [Related]
6. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
Front Immunol; 2020; 11():590494. PubMed ID: 33552049
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
Kowalski B; Valaperti A; Bezel P; Steiner UC; Scholtze D; Wieser S; Vonow-Eisenring M; Widmer A; Kohler M; Franzen D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1711-1720. PubMed ID: 34347128
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
Suzuki Y; Karayama M; Uto T; Fujii M; Matsui T; Asada K; Kusagaya H; Kato M; Matsuda H; Matsuura S; Toyoshima M; Mori K; Ito Y; Koyauchi T; Yasui H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
J Thorac Oncol; 2020 Aug; 15(8):1317-1327. PubMed ID: 32289515
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases.
Hammer B; Bal C; Gysan M; Zehetmayer S; Geleff S; Zech A; Kramer M; Ayazseven S; Idzko M; Mosleh B; Hoda MA; Gompelmann D
Clin Exp Med; 2023 Dec; 23(8):5177-5182. PubMed ID: 37535195
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
[TBL] [Abstract][Full Text] [Related]
13. Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis.
Chen J; Song S; Liu Y; Liu D; Lin Y; Ge S; Ascherman DP
Int J Rheum Dis; 2018 Jul; 21(7):1398-1405. PubMed ID: 29968330
[TBL] [Abstract][Full Text] [Related]
14. Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients With Rheumatoid Arthritis-Associated and Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease.
Nakazawa M; Suzuki K; Takeshita M; Inamo J; Kamata H; Ishii M; Oyamada Y; Oshima H; Takeuchi T
Arthritis Rheumatol; 2021 Apr; 73(4):576-586. PubMed ID: 33038063
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of CCL18 in bronchoalveolar lavage fluid of connective tissue disease-associated interstitial lung disease].
He XW; Luo QZ; Shang Y; Gao ZC
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(38):2976-2981. PubMed ID: 31607028
[No Abstract] [Full Text] [Related]
16. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
17. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.
Vasakova M; Sterclova M; Kolesar L; Slavcev A; Pohunek P; Sulc J; Skibova J; Striz I
Scand J Immunol; 2009 Mar; 69(3):268-74. PubMed ID: 19281539
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease.
Manabe T; Iwayama K; Chuma M; Tasaki Y; Matsumoto S
In Vivo; 2023; 37(3):1260-1265. PubMed ID: 37103090
[TBL] [Abstract][Full Text] [Related]
19. Elevated α-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease.
Sakamoto N; Ishimoto H; Kakugawa T; Satoh M; Hasegawa T; Tanaka S; Hara A; Nakashima S; Yura H; Miyamura T; Koyama H; Morita T; Nakamichi S; Obase Y; Ishimatsu Y; Mukae H
BMC Pulm Med; 2018 Mar; 18(1):44. PubMed ID: 29530007
[TBL] [Abstract][Full Text] [Related]
20. T cell immunity in interstitial lung disease with non-small cell lung cancer patients.
Isono T; Iwahori K; Yanagawa M; Yamamoto Y; Tone M; Haruna M; Hirata M; Fukui E; Kimura T; Kanou T; Ose N; Funaki S; Takeda Y; Morii E; Kumanogoh A; Shintani Y; Wada H
Lung Cancer; 2023 Aug; 182():107278. PubMed ID: 37321075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
